ClinicalTrials.gg
CompletedNCT05041257PICCOLOUpdated Jan 9, 2026Results posted

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

A Phase 2 interventional study of Mirvetuximab soravtansine in Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by AbbVie. Completed at 35 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. mirvetuximab soravtansine · Ovarian Neoplasms.

Enrollment
7th of 12
79 · median 80
Started
2021
with 1 other
Phase 2
6 of 12
4 open now
Registered
5th of 12
by date
Lead sponsor
4 of 12
AbbVie

Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 5th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mirvetuximab soravtansine

mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, or all of them as a file.
02

Study summary

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Read the detailed description

Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed for the treatment of participants with recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Participants will have had at least 2 prior lines of therapy. These will include at least 2 lines of platinum-containing therapy or 1 line with a documented platinum allergy. FRα positivity will be defined by the Ventana FOLR1 (FOLR1- 2.1) CDx assay (Ventana FOLR1 Assay).

03

Conditions studied

  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Platinum-sensitive
  • Ovarian cancer
  • Folate-receptor alpha expression
  • Antibody-drug conjugate
  • Cancer
  • Ovarian Neoplasma
  • Recurrent Platinum-Sensitive
  • High-Grade Ovarian
  • PICCOLO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥ 18 years of age
  2. Participants must have an Performance Status (ECOG PS) of 0 or 1
  3. Participants must have a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer
  4. Participants must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of most recent platinum therapy Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression
  5. Participants must have progressed radiographically on or after their most recent line of anticancer therapy
  6. Participants must have at least 1 lesion that meets the definition of by Version 1.1 (RECIST v1.1) (radiologically measured by the Investigator)
  7. Participants must be willing to provide an block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity
  8. Participant's tumor must be positive for FRα expression as defined by the Ventana FOLR1 Assay
  9. Prior anticancer therapy

    1. Participants must have received at least 2 prior systemic lines of platinum therapy and be considered by the Investigator as appropriate for single-agent non-platinum therapy (documentation required - for example, high risk of reaction; risk of further cumulative toxicity with additional platinum, including but not limited to myelosuppression, neuropathy, renal insufficiency or other) i. Note: Participants who have had a documented platinum allergy may have had only 1 prior line of platinum
    2. Participants may have received up to but no more than 1 prior independent non-platinum cytotoxic therapy
    3. Participants must have had testing for breast cancer susceptibility gene (BRCA) mutation (tumor or germline) and, if positive, must have received a prior poly (ADP-ribose) polymerase (PARP) inhibitor as either treatment or maintenance therapy
    4. ± adjuvant therapies are considered 1
    5. Maintenance therapy (for example, bevacizumab, PARP inhibitors) will be considered part of the preceding line of therapy (that is, not counted independently)
    6. Therapy changed due to toxicity in the absence of progression will be considered part of the same line (that is, not counted independently)
  10. Participants must have completed prior therapy within the specified times below:

    1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to first dose of MIRV
    2. Focal radiation completed at least 2 weeks prior to first dose of MIRV
  11. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia)
  12. Participants must have completed any major surgery at least 4 weeks prior to first dose of MIRV and have recovered or stabilized from the side effects of prior surgery prior to first dose of MIRV
  13. Participants must have adequate hematologic, liver and kidney functions defined as:

    1. (ANC) ≥ 1.5 x 10\^9/liter (L) (1500/microliter [μL]) without granulocyte colony-stimulating factor (G-CSF) in the prior 10 days or long-acting white blood cell (WBC) growth factors in the prior 20 days
    2. count ≥ 100 x 10\^9/L (100,000/μL) without platelet transfusion in the prior 10 days
    3. ≥ 9.0 grams (g)/deciliter (dL) without packed red blood cell (PRBC) transfusion in the prior 21 days
    4. Serum creatinine ≤ 1.5 x (ULN)
    5. (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
    6. Serum ≤ 1.5 x ULN (participants with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0 x ULN)
    7. Serum albumin ≥ 2 g/dL
  14. Participants must be willing and able to sign the form (ICF) and to adhere to the protocol requirements
  15. Women of (WCBP) must agree to use highly effective method(s) while on MIRV and for at least 3 months after the last dose
  16. WCBP must have a negative pregnancy test within the 4 days prior to the first dose of MIRV

Exclusion criteria

Exclusion Criteria:

  1. Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/ borderline ovarian tumor
  2. Participants with prior wide-field radiotherapy (RT) affecting at least 20% of the bone marrow
  3. Participants with > Grade 1 peripheral neuropathy per (CTCAE)
  4. Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision
  5. Participants with serious concurrent illness or active infection, including, but not limited to the following:

    1. Active or C infection (whether or not on active antiviral therapy)
    2. (HIV) infection
    3. Active cytomegalovirus infection
    4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV

    Note: Testing at screening is not required for the above infections unless clinically indicated.

  6. Participants with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
  7. Participants with clinically significant cardiac disease including, but not limited to, any of the following:

    1. Myocardial infarction ≤ 6 months prior to first dose
    2. Unstable angina pectoris
    3. Uncontrolled congestive heart failure ( > class II)
    4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
    5. Uncontrolled cardiac arrhythmias
  8. Participants with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment
  9. Participants with a history of cirrhotic liver disease ( Class B or C)
  10. Participants with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis
  11. Participants requiring use of folate-containing supplements (for example, folate deficiency)
  12. Participants with prior to monoclonal antibodies (mAb)
  13. Women who are pregnant or breastfeeding
  14. Participants who received prior treatment with MIRV or other FRα-targeting agents
  15. Participants with untreated or symptomatic central nervous system (CNS)
  16. Participants with a history of other within 3 years prior to enrollment

    Note: Participants with tumors with a negligible risk for metastasis or death (for example, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.

  17. Prior known hypersensitivity reactions to study drugs and/or any of their
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Mirvetuximab Soravtansine

    Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)

    Drug: Mirvetuximab soravtansine

Interventions

  • Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle

    Also known as: MIRV, IMGN853

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1])

    ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

    Time frame: Up to 3 years

Secondary outcomes

  1. Duration of Response (DOR) Assessed by the Investigator Using RECIST v1.1

    DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.

    Time frame: Up to 3 years

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and does not necessarily had a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 3 years

  3. Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

    The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.

    Time frame: Up to 3 years

  4. Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1

    PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to 3 years

  5. Overall Survival Assessed by the Investigator Using RECIST v1.1

    Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.

    Time frame: Up to 3 years

07

Results

Posted Jan 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneMirvetuximab Soravtansine
Started79
Received at least 1 dose of study drug79
Completed0
Not completed79
Withdrew: Death37
Withdrew: Lost to follow-up3
Withdrew: Sponsor decision39

Outcome measures

PrimaryObjective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1])

ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1])
percentage of participantsMirvetuximab Soravtansine
Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1])51.9 (40.4 to 63.3)
SecondaryDuration of Response (DOR) Assessed by the Investigator Using RECIST v1.1

DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.

Time frame:
Up to 3 years
Reported as:
Median · months
Duration of Response (DOR) Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab Soravtansine
Duration of Response (DOR) Assessed by the Investigator Using RECIST v1.18.25 (5.55 to 10.78)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and does not necessarily had a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 3 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMirvetuximab Soravtansine
Number of Participants With Treatment-emergent Adverse Events (TEAEs)78
SecondaryPercentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
percentage of participantsMirvetuximab Soravtansine
Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria74.5 (59.7 to 86.1)
SecondaryProgression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1

PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to 3 years
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab Soravtansine
Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.16.93 (5.85 to 9.59)
SecondaryOverall Survival Assessed by the Investigator Using RECIST v1.1

Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.

Time frame:
Up to 3 years
Reported as:
Median · months
Overall Survival Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab Soravtansine
Overall Survival Assessed by the Investigator Using RECIST v1.127.17 (23.79 to NA)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection to the end of the study. The median time on follow-up was 26.5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirvetuximab Soravtansine37/79 (46.8%)17/79 (21.5%)77/79 (97.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventMirvetuximab Soravtansine
PNEUMONITISRespiratory, thoracic and mediastinal disorders4/79
KERATITISEye disorders1/79
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/79
NAUSEAGastrointestinal disorders1/79
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/79
SUBILEUSGastrointestinal disorders1/79
VOMITINGGastrointestinal disorders1/79
EXTRAVASATIONGeneral disorders1/79
SUPRAPUBIC PAINGeneral disorders1/79
CYSTITISInfections and infestations1/79
Most frequent other events
Showing 10 of 52
Most frequent other events
EventMirvetuximab Soravtansine
VISION BLURREDEye disorders52/79
DRY EYEEye disorders32/79
NAUSEAGastrointestinal disorders29/79
CATARACTEye disorders27/79
KERATOPATHYEye disorders26/79
DIARRHOEAGastrointestinal disorders24/79
ASTHENIAGeneral disorders24/79
NEUROPATHY PERIPHERALNervous system disorders22/79
ARTHRALGIAMusculoskeletal and connective tissue disorders19/79
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations17/79

Baseline characteristics

Safety Population included all participants who received at least 1 dose of mirvetuximab soravtansine.

Age, Continuous
Age, Continuous(years)Mirvetuximab Soravtansine
Mean64.1 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)Mirvetuximab Soravtansine
Female79
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirvetuximab Soravtansine
Hispanic or Latino2
Not Hispanic or Latino68
Unknown or Not Reported9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirvetuximab Soravtansine
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White65
More than one race0
Unknown or Not Reported9
08

Study locations

35 sites
  • City of Hope National Medical Center /ID# 269928
    Duarte, California 91010, United States
  • University of California Los Angeles /ID# 269969
    Los Angeles, California 90095-3075, United States
  • University Colorado Cancer Center /ID# 269930
    Aurora, Colorado 80045-2517, United States
  • Women'S Cancer Care /ID# 269925
    Covington, Louisiana 70433, United States
  • Holy Name Medical Center /ID# 269927
    Teaneck, New Jersey 07666, United States
  • Cleveland Clinic Main Campus /ID# 269922
    Cleveland, Ohio 44195, United States
  • The Mark H Zangmeister Center /ID# 269929
    Columbus, Ohio 43219, United States
  • Women & Infants Hospital /ID# 269923
    Providence, Rhode Island 02905, United States
  • Duplicate_SCRI - Tennessee Oncology /ID# 269921
    Nashville, Tennessee 37203-1632, United States
  • Texas Oncology - South Austin /ID# 269924
    Austin, Texas 78745, United States
  • Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 269926
    Norfolk, Virginia 23502, United States
  • Newcastle Private Hosptial /ID# 269734
    Lambton Heights, New South Wales 2305, Australia
  • Monash Health - Monash Medical Centre /ID# 269735
    Clayton, Victoria 3168, Australia
  • UZ Gent /ID# 269737
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Universitair Ziekenhuis Leuven /ID# 269736
    Leuven, Vlaams-Brabant 3000, Belgium
  • UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 269738
    Namur, 5000, Belgium
  • Centre Armoricain de Radiotherapie Imagerie & Oncologie (CARIO) /ID# 269847
    Plérin, Cotes-d Armor 22190, France
  • Institut de Cancérologie de l'Ouest René Gauducheau /ID# 269846
    Saint-Herblain, Loire-Atlantique 44805, France
  • Centre Leon Berard /ID# 269848
    Lyon, Rhone 69373, France
  • Institut de cancérologie Strasbourg Europe (ICANS) /ID# 269849
    Strasbourg, 67200, France
  • Bon Secours Cork Hospital /ID# 269851
    Cork, T12 DV56, Ireland
  • Waterford Regional Hospital /ID# 269852
    Waterford, X91 ER8E, Ireland
  • Istituto Nazionale Dei Tumori /ID# 269864
    Milan, Milano 20133, Italy
  • Istituto Europeo Di Oncologia /ID# 269860
    Milan, Milano 20141, Italy
  • Istituto Nazionale Tumori Irccs Fondazione G. Pascale /ID# 269863
    Naples, Napoli 80131, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 269861
    Rome, Roma 00168, Italy
  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 269862
    Bologna, 40138, Italy
  • Hospital Universitario Reina Sofia /ID# 269892
    Córdoba, Cordoba 14004, Spain
  • Hospital Universitario de Jaén /ID# 269895
    Jaén, Jaen 23007, Spain
  • Hospital Universitario Vall d'Hebron /ID# 269889
    Barcelona, 08035, Spain
  • Hospital MD Anderson Cancer Center Madrid /ID# 269888
    Madrid, 28033, Spain
  • Hospital Universitario La Paz /ID# 269890
    Madrid, 28046, Spain
  • Hospital Universitario HM Sanchinarro /ID# 269891
    Madrid, 28050, Spain
  • Hospital Universitario Virgen del Rocio /ID# 269894
    Seville, 41013, Spain
  • Hospital Clínico Universitario de Valencia /ID# 269893
    Valencia, 46010, Spain
09

References and documents

Publications

  • Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barquin A, Galvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio Perez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. The efficacy and safety of mirvetuximab soravtansine in FRalpha-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2025 Mar;36(3):321-330. doi: 10.1016/j.annonc.2024.11.011. Epub 2024 Nov 29. PubMed 39617145 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Dec 2024, 37 months.

Results were first posted in Jan 2026, 1 year after primary completion. A results delay was requested in Dec 2024.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 37 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Sep 13, 2021
StartActual
Oct 19, 2021
Primary completionActual
Dec 12, 2024
CompletionActual
Dec 12, 2024
Results delay requested
Dec 3, 2024
Results first posted
Jan 9, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05041257
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Oct 19, 2021
Primary completion
Dec 12, 2024
Completion
Dec 12, 2024
Results posted
Jan 9, 2026
Last update
Jan 9, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion